Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Needham Says Recent Launches To Drive Market Share Recovery For This Eye-Focused MedTech Stock
06:27pm, Tuesday, 04'th Oct 2022 Benzinga
Needham initiated coverage on Glaukos Corp (NYSE: GKOS) with a price target of $66 and a Buy rating.
The analyst writes that GKOS has lost minimally invasive glaucoma surgery (MIGS) market share
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022
02:30pm, Tuesday, 04'th Oct 2022 Benzinga
Upgrades
For Bank of New York Mellon Corp (NYSE:BK), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, Bank of New York Mellon had an EPS of $1.03, compared to year-ago
Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
03:52pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.
Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
01:32pm, Thursday, 08'th Sep 2022
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
09:26am, Thursday, 08'th Sep 2022 Benzinga
Gainers
IMARA Inc. (NASDAQ: IMRA) jumped 74.8% to settle at $2.01 on Wednesday after the company announced it entered into an asset purchase agreement with Cardurion Pharmaceuticals to sell tovinontr
Why Glaukos Stock Zoomed Nearly 19% Higher Today
10:21pm, Wednesday, 07'th Sep 2022 The Motley Fool
Investors were cheered by the latest update from the lab.
Dow Jumps 450 Points; UiPath Shares Slide
06:42pm, Wednesday, 07'th Sep 2022 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones adding around 450 points on Wednesday.
The Dow traded up 1.45% to 31,596.87 while the NASDAQ rose 1.99% to 11,774.77. The S&P 50
Why Glaukos Stock Zoomed Nearly 19% Higher Today
06:21pm, Wednesday, 07'th Sep 2022
Investors were cheered by the latest update from the lab.
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
04:22pm, Wednesday, 07'th Sep 2022 Benzinga
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy.
Quoin Phar
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
03:08pm, Wednesday, 07'th Sep 2022 Benzinga
Glaukos Corporation (NYSE: GKOS) gained 17.3% to $56.40 after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary effica
(GKOS) – What's Going On With Glaukos Stock?
09:16am, Wednesday, 07'th Sep 2022
Glaukos Corp (NYSE: GKOS) shares are trading higher by 1.87% to $49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieve
Why Is Glaukos (GKOS) Down 8.7% Since Last Earnings Report?
03:31pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
02:35pm, Monday, 15'th Aug 2022 Zacks Investment Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
12:02pm, Monday, 15'th Aug 2022
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat
02:04pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.
